Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Purchased by Barclays PLC

Barclays PLC increased its position in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 132.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 120,464 shares of the company’s stock after purchasing an additional 68,688 shares during the period. Barclays PLC owned 0.12% of Poseida Therapeutics worth $345,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of PSTX. Renaissance Technologies LLC lifted its stake in Poseida Therapeutics by 53.4% in the second quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after acquiring an additional 297,500 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Poseida Therapeutics by 62.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 359,197 shares of the company’s stock valued at $1,027,000 after purchasing an additional 138,510 shares in the last quarter. Blair William & Co. IL lifted its position in shares of Poseida Therapeutics by 14.1% during the 2nd quarter. Blair William & Co. IL now owns 1,101,325 shares of the company’s stock worth $3,216,000 after purchasing an additional 136,273 shares during the last quarter. Fred Alger Management LLC acquired a new position in shares of Poseida Therapeutics during the third quarter worth $369,000. Finally, Advantage Alpha Capital Partners LP acquired a new position in shares of Poseida Therapeutics during the third quarter worth $285,000. 46.87% of the stock is owned by hedge funds and other institutional investors.

Poseida Therapeutics Stock Performance

Shares of PSTX stock opened at $9.52 on Friday. The business has a 50 day simple moving average of $6.66 and a 200 day simple moving average of $4.24. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 3.20. The firm has a market capitalization of $930.81 million, a price-to-earnings ratio of -15.11 and a beta of 1.64. Poseida Therapeutics, Inc. has a 12-month low of $1.87 and a 12-month high of $9.65.

Analyst Ratings Changes

Several equities research analysts have recently commented on PSTX shares. William Blair restated a “market perform” rating on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. BTIG Research restated a “neutral” rating on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Piper Sandler lowered shares of Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price target on the stock. in a research note on Monday, December 2nd. Cantor Fitzgerald downgraded shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 26th. Finally, HC Wainwright reiterated a “neutral” rating and set a $9.00 target price (down previously from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Poseida Therapeutics currently has an average rating of “Hold” and a consensus price target of $9.50.

Insider Activity

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total value of $278,100.00. Following the transaction, the chairman now owns 651,291 shares in the company, valued at $6,037,467.57. The trade was a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 2.90% of the stock is owned by corporate insiders.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.